Amaç: Bu çalışmada mide kanserinin (MK) epidemiyolojik ve genel sağkalım (GSK) özelliklerinin araştırılması amaçlanmıştır. Gereç Yöntem: Ege Üniversitesi Kanserle Savaş Uygulama ve Araştırma Merkezine (EÜKAM) 1992- 2017 yıllarında kayıtlı Ege Üniversitesi Tıp Fakültesi Hastanesi kanser verileri retrospektif olarak taranmıştır. CAN-REG-4 bilgisayar programına kayıtlı veriler, Dünya Sağlık Örgütü ve Surveillance, Epidemiology, and End Results sistemlerinde gruplanarak analizler yapılmıştır. İstatistik analizlerde kikare, General Linear Model (GLM), Kaplan Meier sağkalım analizleri uygulanmıştır. Etik kurul onayı alınmıştır. Bulgular: EÜKAM veri tabanına kayıtlı toplam 117.139 kanserden 4.212’si (%3,6) MK’dir. Gastrointestinal sistem kanserler içinde kolorektal kanserlerden sonra ikinci sıklıkta MK (%21,6) yer almıştır. Olguların 2.692’si (%63,9) erkek, 1.520’si (%36,1) kadındır, arasındaki fark istatistiksel olarak anlamlıdır (p
Aim: The aim of this study was to determine the epidemiologic and survival characteristics of gastric cancer (GC) patients. Materials and Methods: Data of Ege University Cancer Control and Research Center (EÜKAM) between 1992-2017 were screened retrospectively. Data recorded in computer program CAN-REG-4 were categorized according to the World Health Organisation and Surveillance, Epidemiology, and End Results systems and analyzed. Chi-square test, General Linear Model, and Kaplan-Meier survival analysis were used for statistical analysis. Ethical approval was obtained. Results: Out of a total of 117,139 cancers registered in the EÜKAM database, 4,212 (3.6%) were GC. Among the gastrointestinal cancers, GC (21.6%) was the second most frequent after colorectal cancers. 2,692 (63.9%) of the patients were male, 1,520 (36.1%) were female, the difference was found significant (p
___
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394-424.
2. Ferlay J, Soerjomataram I, Ervik M et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC Cancer Base No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr, giriş tarihi: 15.07.2020.
3. Yusefi AR, Bagheri Lankarani K, Bastani P, Radinmanesh M, Kavosi Z. Risk Factors for Gastric Cancer: A Systematic Review. Asian Pac J Cancer Prev 2018;19(3):591-603.
4. De Angelis R, Sant M, Coleman MP et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study. Lancet Oncol 2014;15(1):23-34.
5. Lui FH, Tuan B, Swenson SL, Wong RJ. Ethnic disparities in gastric cancer incidence and survival in the USA: an updated analysis of 1992-2009 SEER data. Dig Dis Sci 2014 Dec; 59(12):3027-34.
6. Bosman FT, Carneiro F, Hruban RH et al eds. WHO classification of tumours of the digestive system, vol. 3. 4th ed Lyon: International Agency for Research on Cancer, 2010.
7. Lauren P. The Two Histological Main Types Of Gastric Carcinoma: Diffuse And So-Called Intestinal-Type Carcinoma. An Attempt at a Histo-Clinical Classification. Acta Pathol Microbiol Scand 1965;64:31-49.
8. Haydaroğlu A, Sert F, Caner A. Ege Üniversitesi Hastanesi veri tabanındaki kanser olgularının epidemiyolojik ve genel sağ kalım özellikler. Ege Tıp Dergisi 2019;58 Ek sayı/ Supplement 1-9.
9. TC Sağlık Bakanlığı Kanser İstatistikleri. 2016 Kanser İstatistikleri. Erişim: https://hsgm.saglik.gov.tr/depo/birimler/kanser-db/istatistik/Trkiye_Kanser_statistikleri_2016.pdf (giriş tarihi:15 Temmuz 2020).
10.Yalçın B, Zengin N, Aydın F et al. The clinical and pathological features of patients with gastric cancer in Turkey: A Turkish Oncology Group Study. Turkish Journal of Cancer 2006;36(3):108-115.
11.Bor S, Vardar R, Ormeci N et al. Prevalence patterns of gastric cancers in Turkey: model of a developing country with high occurrence of Helicobacter pylori. J Gastroenterol Hepatol 2007 Dec; 22(12):2242-5.
12. Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2017, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2017/, based on November 2019 SEER data submission, posted to the SEER web site, April 2020.
13. Tural D, Selçukbiricik F, Akar E, Serdengeçti S, Büyükünal E. Gastric cancer: A case study in Turkey. J Can Res Ther 2013;9(4):644-8.
14.Kaneko S, Yoshimura T. Time trend analysis of gastric cancer incidence in Japan by histological types, 1975- 1989. Br J Cancer 2001;84(3):400-5.
15.Schwartz GK. Invasion and metastases in gastric cancer: in vitro and in vivo models with clinical correlations. Semin Oncol 1996;23(3):316-24.
16.Polkowski W, van Sandick JW, Offerhaus GJ, et al. Prognostic value of Laurén classification and c-erbB-2 oncogene overexpression in adenocarcinoma of the esophagus and gastroesophageal junction. Ann Surg Oncol 1999;6(3):290-7
17.Parsonnet J, Vandersteen D, Goates J, et al. Helicobacter pylori infection in intestinal- and diffuse-type gastric adenocarcinomas. J Natl Cancer Inst 1991;83(9):640-3
18. Qiu MZ, Cai MY, Zhang DS, et al. Clinicopathological characteristics and prognostic analysis of Lauren classification in gastric adenocarcinoma in China. J Transl Med 2013;11:58.
19.Stiekema J, Cats A, Kuijpers A, et al. Surgical treatment results of intestinal and diffuse type gastric cancer. Implications for a differentiated therapeutic approach?. Eur J Surg Oncol 2013;39(7):686-93.
20. National Cancer Institute. Surveillance, epidemiology and end results: incidance, stomach cancer. Available from: http://seer.cancer.gov/statfacts/html/stomach.html, giriş tarihi:15.07.2020